NCT00508287View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Type 2 Diabetes
Interventions
DRUG

BMS-686117

Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.

DRUG

Byetta

Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.

DRUG

Placebo

Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33169

Elite Research Institute, Miami

37920

New Orleans Center For Clinical Research, Knoxville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY